CLNN.US Clene Inc.

Consumer Defensive Biotechnology USA Stocks
3.92 USD
Close of Nov 14, 2026
3.02 10.84
Market cap
USD 56.4M
P/E
-
P/B
7.83x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is CLNN.US undervalued?

Graham number

The Graham number of Clene Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Clene Inc. fundamental analysis

No fundamental analysis for Clene Inc. yet.

Clene Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Clene Inc.

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The company's lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients w…

Full company profile